Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Non-Current Deffered Revenue: 2017-2025

Historic Non-Current Deffered Revenue for Protagonist Therapeutics (PTGX) over the last 6 years, with Sep 2025 value amounting to $2.8 million.

  • Protagonist Therapeutics' Non-Current Deffered Revenue fell 83.11% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year decrease of 83.11%. This contributed to the annual value of $11.7 million for FY2024, which is N/A change from last year.
  • Per Protagonist Therapeutics' latest filing, its Non-Current Deffered Revenue stood at $2.8 million for Q3 2025, which was down 48.13% from $5.4 million recorded in Q2 2025.
  • In the past 5 years, Protagonist Therapeutics' Non-Current Deffered Revenue registered a high of $28.9 million during Q1 2024, and its lowest value of $2.8 million during Q3 2025.
  • Moreover, its 2-year median value for Non-Current Deffered Revenue was $11.7 million (2024), whereas its average is $13.5 million.
  • Data for Protagonist Therapeutics' Non-Current Deffered Revenue shows a maximum YoY crashed of 83.11% (in 2025) over the last 5 years.
  • Protagonist Therapeutics' Non-Current Deffered Revenue (Quarterly) stood at $11.7 million in 2024, then slumped by 83.11% to $2.8 million in 2025.
  • Its Non-Current Deffered Revenue stands at $2.8 million for Q3 2025, versus $5.4 million for Q2 2025 and $8.2 million for Q1 2025.